IL4R and neoplasm: IL4R-Abx decreased the population of Ki67+ proliferating cells and IL4R-expressing cells in tumor tissues more efficiently than Abx when systemically administered at 10 weeks of age (5 mg/kg body weight, weekly for 4 weeks) (Figure S11B).